These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 20460483)

  • 1. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
    Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
    J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
    Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
    J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
    Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
    Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
    Ko K; Yamazaki S; Nakamura K; Nishioka T; Hirota K; Yamaguchi T; Shimizu J; Nomura T; Chiba T; Sakaguchi S
    J Exp Med; 2005 Oct; 202(7):885-91. PubMed ID: 16186187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
    Fecci PE; Ochiai H; Mitchell DA; Grossi PM; Sweeney AE; Archer GE; Cummings T; Allison JP; Bigner DD; Sampson JH
    Clin Cancer Res; 2007 Apr; 13(7):2158-67. PubMed ID: 17404100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
    J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
    Kocak E; Lute K; Chang X; May KF; Exten KR; Zhang H; Abdessalam SF; Lehman AM; Jarjoura D; Zheng P; Liu Y
    Cancer Res; 2006 Jul; 66(14):7276-84. PubMed ID: 16849577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of regulatory T cells to glucocorticoid-induced [corrected] TNFR family-related protein (GITR) during Plasmodium yoelii infection.
    Hisaeda H; Hamano S; Mitoma-Obata C; Tetsutani K; Imai T; Waldmann H; Himeno K; Yasutomo K
    Eur J Immunol; 2005 Dec; 35(12):3516-24. PubMed ID: 16304635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity.
    Haque A; Stanley AC; Amante FH; Rivera Fde L; Zhou Y; Kuns RD; Yardley V; Sakaguchi S; Hill GR; Engwerda CR
    J Immunol; 2010 Mar; 184(5):2583-92. PubMed ID: 20139272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity.
    Kamimura Y; Iwai H; Piao J; Hashiguchi M; Azuma M
    J Immunol; 2009 Mar; 182(5):2708-16. PubMed ID: 19234165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
    Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
    Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
    Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
    Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.